What are the ethical issues surrounding gene therapy?

Somatic gene therapy targets non-reproductive cells, such as those in the liver or blood, meaning the genetic changes are not passed on to offspring. This approach is currently used in clinical treatments and is generally considered ethically acceptable because the patient consents to the changes. Germline gene therapy targets eggs, sperm, or embryos, meaning the changes are heritable and affect all future generations. This is highly controversial because future generations cannot consent, and there is a risk of unintended long-term consequences or off-target effects that could disrupt the human gene pool. Most countries, including the U.S., prohibit federal funding for germline editing research due to these ethical and safety concerns. How does the high cost of gene therapy affect healthcare equity and access?::Gene therapies are among the most expensive medical treatments available, with some costing over a million dollars per patient. This high cost raises significant ethical concerns about equity, as it may only be accessible to wealthy individuals or those with comprehensive insurance coverage, potentially creating a two-tiered system of health. There is a risk that these life-saving treatments will exacerbate existing health disparities, leaving lower-income populations without access to advanced care. Policymakers and healthcare systems are grappling with how to fund these therapies sustainably while ensuring fair distribution and preventing financial ruin for patients and families. Can gene therapy be used for enhancement rather than disease treatment, and is that ethical?::Currently, gene therapy is approved and researched primarily for treating serious genetic diseases. The use of gene editing for enhancement, such as increasing height, intelligence, or athletic ability, is not currently possible with approved technologies and is widely considered ethically problematic. Critics argue that enhancement could lead to a new form of social inequality, where the wealthy can "buy" superior traits, reducing social mobility and acceptance of natural diversity. Furthermore, the long-term safety of modifying healthy genes for non-medical purposes is unknown, posing risks to the individual and potentially to future generations if germline editing were involved. Who decides which genetic conditions are worth treating with gene therapy?::The decision involves a complex interplay of scientific, medical, and societal factors. Clinically, conditions with a clear genetic cause, severe impact on quality of life, and lack of effective alternative treatments are prioritized. Ethically, there is ongoing debate about how to define "disability" or "disease," as some traits may be viewed as disorders by one group and normal variation by another. Regulatory bodies, such as the FDA, assess safety and efficacy, while bioethicists and patient advocacy groups influence the prioritization of research. The goal is to balance the urgency of treating severe conditions with the need to avoid stigmatizing certain genetic variations or allocating resources in a way that ignores less severe but common conditions.